Lipidomic profiling of plasma from patients with multiple myeloma receiving bortezomib: an exploratory biomarker study of JCOG1105 (JCOG1105A1).
Ri M, Iida S, Saito K, Saito Y, Maruyama D, Asano A, Fukuhara S, Tsujimura H, Miyazaki K, Ota S, Fukuhara N, Negoro E, Kuroda J, Yoshida S, Ohtsuka E, Norifumi T, Tabayashi T, Takayama N, Saito T, Suzuki Y, Harada Y, Mizuno I, Yoshida I, Maruta M, Takamatsu Y, Katsuya H, Yoshimitsu M, Minami Y, Kanato K, Munakata W, Nagai H.
Ri M, et al. Among authors: suzuki y.
Cancer Chemother Pharmacol. 2025 Jan 24;95(1):29. doi: 10.1007/s00280-025-04752-1.
Cancer Chemother Pharmacol. 2025.
PMID: 39853402
Clinical Trial.